While advances in immunotherapy have resulted in remarkable clinical responses in some patients, there will be >14 million new cases of cancer diagnosed in 2020 with >8 million deaths. Resistant and recurrent aggressive metastatic disease is the cause of <90% of these deaths in modern economic societies. Aberrant migration and proliferation of cancer cells are the hallmarks of tumor metastasis and resistant buildup therefore it is an attractive pathway for anti-cancer modalities.

BioKine is a private, well integrated, VC-funded and revenue garnering entity. Its leading product, BL-8040 (BKT-140) is co-developed with BiolineRx (NASDAQ:BLRX) for multiple indications, including: Stem Cell Mobilization (Ph-3) , AML (Ph-2b), Pancreatic Carcinoma in combo with Chemo and anti-PD-1/KEYTRUDA (Ph-2a). Biokine has developed a suite of unique technologies to target cancer- MigHit™ and ImmunHit™ -and is conducting advanced preclinical research on novel drug candidates discovered in-house.

Biokine’s BKT-300 is a first in class small molecule that specifically controls migration and survival pathways in cancer cells via targeting the protein regulator of cytokinesis 1 (PRC1). BKT-300 was Identified, utilizing Biokin’s Might™ phenotypic screen.

BKT-300 is in IND enabling studies; 12 months to IND-submission. Phase I/II dose finding study, will evaluate safely and initial efficacy in patients with aggressive solid tumors that have high Ki67 and CDC25c expression. BKT-300 has a strong worldwide IP coverage (life span till 2042) including composition of matter and method of use patents.

Key R&D and MOA finding achieved today include the following features:

• Selectively binds and inhibits the function of PRC-1, a new validated tumor target.
• Specifically induces cell cycle arrest and apoptosis of tumour cells but not normal cells.
• Down regulates the expression of CDC25c (cell division cycle 25C) in tumor cells
• Upregulates CDC p21 (cyclin-dependent kinase inhibitor) in tumor cells.
• Inhibit cancer cell migration by inhibiting the of F-actin and microtubules formation.
• Induces cell cycle arrest and apoptosis only in tumour cells but not normal cells.

• In-vitro: Synergizes with SoC therapies in inhibiting tumor cell growth including:

BCL-2 inhibitor Ventoclax, topoisomerase inhibitor Irinotecan and alkylating agent Temozolomide.

• In-vivo: Demonstrated potent inhibition of tumor growth in multiple models including PDXs with high Ki67 and CDC25c expression.

Biokine is managed by a team of Biopharma veterans with a proven track records taking drugs from idea to advance clinical studies